Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report

Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report

In recent years, immune checkpoint inhibitors (ICIs), represented by PD-1/PD-L1 monoclonal antibodies, have become a research hotspot in the field of oncology treatment. Immunotherapy has shown significant survival advantages in a variety of solid tumors. However, the phenomenon of hyperprogressive...

Full description

Bibliographic Details
Main Authors:	Changshun Wu, Kai Zhou, Yan Zheng, Dongxiao Lv, Miaoqing Zhao, Yue Hu, Fei Qi, Xin Wang, Hong Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Series:	Frontiers in Oncology
Subjects:	non-small cell lung cancer CD8+PD-L1+ hyperprogressive disease PD-L1 durvalumab
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.969493/full

Similar Items

Hyperprogression: A novel response pattern under immunotherapy
by: Xue‐jiao Han, et al.
Published: (2020-09-01)

Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
by: Wang X, et al.
Published: (2023-01-01)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
by: Yanping Li, et al.
Published: (2023-05-01)

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Tomas Jelinek, et al.
Published: (2018-11-01)

Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
by: Marjorie Faure, et al.
Published: (2018-04-01)

Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report
by: Romain Varnier, et al.
Published: (2021-09-01)

Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
by: Shaohua Li, et al.
Published: (2024-10-01)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023-08-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
by: Yu-Min Zhong, et al.
Published: (2022-10-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer
by: Nong Y, et al.
Published: (2024-12-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

PD-1/PD-L Axis in Neuroinflammation: New Insights
by: Susanna Manenti, et al.
Published: (2022-06-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
by: Siqing Jiang, et al.
Published: (2022-09-01)

Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients
by: Zeinab Rajabian, et al.
Published: (2019-03-01)

The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
by: Weiting Qin, et al.
Published: (2019-10-01)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
by: Peng Ding, et al.
Published: (2023-05-01)

PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy
by: Andrei Gurau, et al.
Published: (2025-06-01)

Research Progress of PD-1/PD-L1/2 Pathway in Multiple Myeloma
by: MA Yinjuan, et al.
Published: (2021-06-01)

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer
by: Olga Yajuk, et al.
Published: (2021-06-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma
by: Bo Zhou, et al.
Published: (2022-06-01)

Association of PD-1 and PD-L1 protein expression with selected clinical and morphological parameters in colorectal cancers
by: Paulina Poter, et al.
Published: (2024-05-01)

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
by: Xiaohui Ren, et al.
Published: (2024-04-01)

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs
by: Sara Zalba, et al.
Published: (2020-06-01)

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice
by: Shanshan (Jenny) Zhong, et al.
Published: (2024-07-01)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020-05-01)

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
by: Song Xue, et al.
Published: (2017-04-01)

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
by: Maria-Luisa del Rio, et al.
Published: (2022-06-01)

Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a single-arm meta-analysis
by: Jie Yang, et al.
Published: (2024-08-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD)
by: Stefania Angelicola, et al.
Published: (2025-01-01)

PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief
by: Daling Deng, et al.
Published: (2024-04-01)